Emergent BioSolutions (EBS) Non Operating Interest Expenses (2011 - 2026)
Emergent BioSolutions (EBS) posted Non Operating Interest Expenses of $10.0 million for Q2 2026, down 9.09% on a QoQ basis from $11.0 million in Q1 2026, and down 31.97% year-over-year from $14.7 million in Q2 2025.
Powered by 
Analysis
Emergent BioSolutions (EBS) Non Operating Interest Expenses (2011 - 2026) Analysis & Trends
Emergent BioSolutions has reported Non Operating Interest Expenses for 16 years, with the latest figure at $10.0 million in Q2 2026.
- On a quarterly basis, Non Operating Interest Expenses fell 31.97% year-over-year to $10.0 million in Q2 2026; TTM through Jun 2026 was $50.9 million, a 3.05% decrease from a year earlier, with the FY2025 full-year figure at $59.3 million, down 16.48% from the prior year.
- Non Operating Interest Expenses was $10.0 million for Q2 2026 at Emergent BioSolutions, down from $11.0 million in the prior quarter.
- The five-year high for Non Operating Interest Expenses was $28.6 million in Q2 2023, with the low at $7.8 million in Q2 2022.
- Average Non Operating Interest Expenses over 5 years is $15.4 million, with a median of $14.7 million recorded in 2025.
- The sharpest annual moves came in 2023 and 2024: Non Operating Interest Expenses soared 266.67% in 2023, then slumped 57.87% in 2024.
- Over 5 years, Non Operating Interest Expenses stood at $12.8 million in 2022, then surged by 69.53% to $21.7 million in 2023, then sank by 31.8% to $14.8 million in 2024, then slipped by 0.68% to $14.7 million in 2025, then tumbled by 31.97% to $10.0 million in 2026.
- The last three Non Operating Interest Expenses figures came in at $10.0 million (Q2 2026), $11.0 million (Q1 2026), and $14.7 million (Q4 2025), per Business Quant data.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non Operating Interest Expenses (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 649.47 Bn | 628.71 Bn | 17.26 Bn | 281.00 Mn |
| 2 | AbbVie | 467.46 Bn | 460.93 Bn | 12.70 Bn | - |
| 3 | Merck | 369.31 Bn | 362.22 Bn | 12.21 Bn | - |
| 4 | Novartis Ag | 269.03 Bn | 261.74 Bn | 11.24 Bn | -462.00 Mn |
| 5 | Pfizer | 158.11 Bn | 146.71 Bn | 10.94 Bn | - |
| 6 | Bristol Myers Squibb | 127.96 Bn | 116.89 Bn | 9.25 Bn | - |
| 7 | Sanofi | 51.83 Bn | 44.86 Bn | 10.79 Bn | -333.60 Mn |
| 8 | BeOne Medicines | 41.33 Bn | 36.23 Bn | 1.53 Bn | 39.74 Mn |
| 9 | Revolution Medicines | 41.30 Bn | 41.30 Bn | - | 23.78 Mn |
| 10 | Emergent BioSolutions | 335.50 Mn | 194.60 Mn | 137.20 Mn | 10.00 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 10.00 Mn |
| Mar 31, 2026 | 11.00 Mn |
| Dec 31, 2025 | 14.70 Mn |
| Sep 30, 2025 | 15.20 Mn |
| Jun 30, 2025 | 14.70 Mn |
| Mar 31, 2025 | 14.70 Mn |
| Dec 31, 2024 | 14.80 Mn |
| Sep 30, 2024 | 8.30 Mn |
| Jun 30, 2024 | 23.60 Mn |
| Mar 31, 2024 | 24.30 Mn |
| Dec 31, 2023 | 21.70 Mn |
| Sep 30, 2023 | 19.70 Mn |
| Jun 30, 2023 | 28.60 Mn |
| Mar 31, 2023 | 17.90 Mn |
| Dec 31, 2022 | 12.80 Mn |
| Sep 30, 2022 | 8.50 Mn |
| Jun 30, 2022 | 7.80 Mn |
| Mar 31, 2022 | 8.20 Mn |
| Dec 31, 2021 | 9.00 Mn |
| Sep 30, 2021 | 8.40 Mn |
API Access
Emergent BioSolutions Non Operating Interest Expenses API
Pull this series into your own models, spreadsheets and apps with the Business Quant
Historical Metrics API. The request below matches the chart above — change the
frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.
https://data.businessquant.com/historic?slug=non-operating-interest-expenses&ticker=EBS&period=max&api_key=YOUR_API_KEYimport requests
url = "https://data.businessquant.com/historic"
params = {"slug": "non-operating-interest-expenses", "ticker": "EBS", "period": "max", "api_key": "YOUR_API_KEY"}
data = requests.get(url, params=params).json()const res = await fetch("https://data.businessquant.com/historic?slug=non-operating-interest-expenses&ticker=EBS&period=max&api_key=YOUR_API_KEY");
const data = await res.json();